ArTara Therapeutics, Inc.旗下疗法Tara-002在针对BCG无应答型非肌层浸润性膀胱癌的临床研究中,取得了令人瞩目的成果。数据显示,在为期六个月的评估期内,该疗法的完全缓解率达到了68%。
ArTara Therapeutics, Inc.旗下疗法Tara-002在针对BCG无应答型非肌层浸润性膀胱癌的临床研究中,取得了令人瞩目的成果。数据显示,在为期六个月的评估期内,该疗法的完全缓解率达到了68%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.